Medline share weakness overdone, ‘misinterpretation’-driven, says Leerink

The decline in Medline (MDLN) shares appears overdone and likely driven by a misinterpretation of an FDA-related headline, as the affected products are tied to a third-party supplier and have no meaningful financial impact, Leerink tells investors in a research note. The issue does not signal broader quality or regulatory risks, suggesting the move is sentiment-driven rather than fundamental, with more clarity expected on the upcoming earnings call. The firm maintains an Outperform rating on the shares.